NCT05639166View on ClinicalTrials.gov

Study in Adults to Assess the Safety and Efficacy of Inhaled IBIO123, for Post-exposure Prophylaxis of COVID-19

PHASE2CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

February 18, 2023

Primary Completion Date

May 16, 2023

Study Completion Date

May 16, 2023

Conditions
COVID-19
Interventions
BIOLOGICAL

IBIO123

IBIO123 10 mg

OTHER

Placebo

Matching Placebo

Trial Locations (5)

43005

Volyn Regional Clinical Hospital, Lutsk

58005

Central City Clinical Hospital of Chernivtsi City Council, Chernivtsi

76018

City Clinical Hospital #1 of Ivano-Frankivsk City Council, Ivano-Frankivsk

76025

Central C.H. of Ivano-Frankivsk, Ivano-Frankivsk

0183

Jongaie Research, Pretoria West

Sponsors
All Listed Sponsors
lead

Immune Biosolutions Inc

INDUSTRY